Faeth: PIKTOR pivotal trial design expected 1H 2027 after Phase 2 endometrial dataNov 13Clinical readoutAbvc Biopharma, Inc.Actuate Therapeutics Inc.Updated
Lilly posts Phase 2b retatrutide renal results; registers tersolisib kidney PK studyNov 13Weekly roundup, 10 itemsabemaciclibanastrozole
Gilead posts ZUMA-24 results for axi-cel in LBCL; denikitug trial still active, not recruitingNov 12Weekly roundup, 2 itemsaxicabtagene ciloleuceldenikitugUpdated
Adagene completes enrollment in Phase 2 muzastotug dose-optimization trial for MSS colorectal cancerNov 9Trial updateAdagene Inccisplatin
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Merck collaborator posts pancreatic cancer results; new MK-1045, COPD trial records surfaceNov 6Weekly roundup, 14 itemsDaiichi SankyoensifentrineUpdated
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
AstraZeneca's FORTUNA misses in NASH as ARTEMIS kidney trial ends for lack of efficacyOct 30Weekly roundup, 8 itemsalbuterol sulfate and budesonideAstraZenecaUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Merck's KEYNOTE-522 posts results in triple negative breast cancer; new PAH study starts in IndiaOct 22Weekly roundup, 5 itemsMerck & Co., Inc.pembrolizumabUpdated
Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trialsOct 22Weekly roundup, 11 itemscetuximabdulaglutide
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
BeOne Medicines registers Phase 1 trial of BG-T0050 in DLBCL and other B-cell cancersOct 21Weekly roundup, 5 itemsazacitidineBeiGene
Arcus Biosciences' ARC-10 lung cancer trial listed as completed as of Oct 2026 updateOct 19Trial updateArcus Biosciences, Inc.domvanalimab
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows updateOct 9Weekly roundup, 9 itemsalectinibcisplatinUpdated
GSK discloses FDA hold on infant pneumococcal vaccine study; posts two Phase 3/4 resultsOct 9Weekly roundup, 9 itemsdostarlimab-gxlyGlaxoSmithKlineUpdated
Actuate Therapeutics files S-1 for 50 million share offering on NasdaqOct 6FinancingActuate Therapeutics Inc.
Corcept's ROSELLA Phase 3 posts results for relacorilant plus nab-paclitaxel in ovarian cancerSep 25Trial updateCorcept Therapeuticspaclitaxel
Corcept names Justin Gunn to succeed retiring endocrinology president Sean MaduckSep 23PeopleCorcept Therapeutics
FDA tells Compass Therapeutics to run survival trial before BLA for tovecimigSep 22Clinical readoutCompass Therapeutics
Teva gets labeling supplement approved for injectable PaclitaxelSep 11Regulatory decisionpaclitaxelTeva Pharmaceutical Industries Ltd
Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
AbbVie posts results from terminated emraclidine trial, opens two studies to recruitmentAug 21Weekly roundup, 4 itemsAbbVieemraclidine
Can-Fite reports preclinical data on namodenoson-gemcitabine combination in pancreatic cancerAug 17Clinical readoutCan-Fite BioPharmagemcitabine
RenovoRx completes Phase III enrollment, raises 2026 revenue guidanceAug 13Quarterly updateRenovoRx, Inc
Eikon Therapeutics reports Q2 2026 results with seven ESMO abstracts and melanoma trial progressAug 13Quarterly updateEikon Therapeutics
Theriva doses first patients in VIRAGE2 trial of VCN-01 in pancreatic cancerAug 11Quarterly updateTheriva Biologics, Inc.
MD Anderson registers Phase II trial of Summit's ivonescimab in rare appendix cancerAug 10Trial updateivonescimabSummit Therapeutics
Puma Biotechnology raises 2026 guidance on NERLYNX demand, details alisertib trial timelineAug 6Quarterly updatealisertibneratinib
Compass Therapeutics awaits FDA input on tovecimig biliary cancer dataAug 6Quarterly updateCompass Therapeutics
Theriva doses first patient in VIRAGE2 trial testing repeat VCN-01 dosing in pancreatic cancerAug 6Trial updateTheriva Biologics, Inc.
ROCKIF trial of defactinib in ovarian cancer terminated for lost funding; results postedJul 31Trial updatedefactinibVerastem, Inc.
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
Theriva gets Spanish authorization for VIRAGE2 trial of VCN-01 in pancreatic cancerJul 7Clinical readoutTheriva Biologics, Inc.
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Sanofi posts pediatric Hectorol results; USC germ cell trial data also reportedJul 2Weekly roundup, 4 itemsdoxercalciferolSanofi